Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 10Neoplasms 6Prostatic Neoplasms 5Anxiety Disorders 5Leukemia 4Uterine Cervical Neoplasms 3Stomach Neoplasms 3Ovarian Neoplasms 3Neoplasms, Plasma Cell 3Neoplasm Metastasis 3Multiple Myeloma 3Lymphoma 3Fatigue 3Depression 3Colorectal Neoplasms 3Rectal Neoplasms 2Primary Myelofibrosis 2Hodgkin Disease 2Hematologic Neoplasms 2Head and Neck Neoplasms 2Gastrointestinal Stromal Tumors 2Gastrointestinal Neoplasms 2Endometrial Neoplasms 2Colonic Neoplasms 2Anus Neoplasms 2cyclopia sequence 1Vulvar Neoplasms 1Vomiting 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1

Interventions

valrubicin 2Mitomycin 2Gemcitabine 2enfortumab vedotin 1durvalumab 1advexin 1Surveys and Questionnaires 1Standard of Care 1Oncolytic Virotherapy 1Nivolumab 1Interferons 1Cystoscopy 1Biopsy 1ALT-801 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma in Situ × Surveys and Questionnaires × Clear all
NCT03106610 2018-05-24

Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy

M.D. Anderson Cancer Center

Phase 1 Terminated
1 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡